The role of fixed dose combinations in the treatment of primary open-angle glaucoma

Vestnik oftalmologii
S Yu PetrovA V Volzhanin

Abstract

A great number of patients with primary open-angle glaucoma require combination therapy with several hypotensive drugs of different pharmacological groups to efficiently compensate the intraocular pressure (IOP) and prevent further development of glaucoma. Although glaucoma treatment usually starts with monotherapy, several preparations administered simultaneously have stronger hypotensive effect further increased by their additive action. However, the increased frequency of instillations may lead to drug washout and decreased patient compliance. Fixed dose combinations (FDCs) are a pharmacological form of eye drops that combines two or more active drugs in a single dosage form. The frequency of FDCs administration does not exceed two per day, which is convenient for long-term application and helps improve patient compliance. FDCs tolerability tends to be higher than that of simultaneous instillations of separate monotherapy drugs, while the hypotensive in clinical trials is comparable, in some real practice trials is superior. A review of existing studies showed that FDCs are superior to monotherapy in terms of cost-effectiveness. The use of FDCs was found to be beneficial for glaucoma treatment from the viewpoints of both rea...Continue Reading

References

May 1, 1989·Australian and New Zealand Journal of Ophthalmology·S M PodosJ B Serle
Mar 1, 1974·Journal of Pharmaceutical Sciences·S S ChraiJ R Robinson
Oct 9, 2002·Archives of Ophthalmology·Anders HeijlUNKNOWN Early Manifest Glaucoma Trial Group
Nov 7, 2002·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sarah A TaylorRichard P Mills
Jan 14, 2003·Archives of Ophthalmology·M Cristina LeskeUNKNOWN Early Manifest Glaucoma Trial Group
Jul 2, 2005·American Journal of Ophthalmology·Howard S BarnebeyMichael V W Bergamini
Jul 13, 2005·Archives of Ophthalmology·Anastasios G P KonstasWilliam C Stewart
Nov 3, 2005·Ophthalmology·Michael DiestelhorstUNKNOWN European-Canadian Latanoprost Fixed Combination Study Group
Nov 9, 2005·Journal of Glaucoma·Jean Philippe NordmannGilles Berdeaux
Jun 15, 2007·Advances in Therapy·Stephan DunkerUNKNOWN Latanoprost/Timolol Fixed Combination Study Group
Nov 21, 2007·Drugs & Aging·Albert S KhouriRobert D Fechtner
Mar 14, 2008·Current Pharmaceutical Design·Francesco MincioneClaudiu T Supuran
Jun 11, 2008·Archives of Ophthalmology·Thomas BramleyJan E Hansen
Aug 13, 2008·Archives of Ophthalmology·Balwantray C ChauhanUNKNOWN Canadian Glaucoma Study Group
Aug 30, 2008·Drugs & Aging·Carroll A B WebersJan S A G Schouten
Dec 17, 2008·Survey of Ophthalmology·Carol B TorisPaul L Kaufman
Feb 26, 2009·Current Opinion in Ophthalmology·Harmohina BaggaRobert N Weinreb
Mar 20, 2009·Journal of Glaucoma·Fawzia DjafariJean Lachaine
Sep 8, 2009·Current Medical Research and Opinion·Eve J HigginbothamAngela Guckian
Feb 1, 2012·Acta Ophthalmologica·Aukje van GestelJan S Schouten
Feb 22, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Quang H NguyenStephen M Goode
Apr 5, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Anastasios G P KonstasJohn R Samples

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.